Cargando…

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-common hematologic malignancy. Despite advances in therapy, MM remains largely incurable. Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, which is highly expressed on myeloma cells, and the antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campbell, Kerry S., Cohen, Adam D., Pazina, Tatiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230619/ https://www.ncbi.nlm.nih.gov/pubmed/30455698 http://dx.doi.org/10.3389/fimmu.2018.02551

Ejemplares similares

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
por: Taniwaki, Masafumi, et al.
Publicado: (2018)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
por: Bose, Prithviraj, et al.
Publicado: (2023)

Elotuzumab for multiple myeloma
Publicado: (2022)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
por: Pazina, Tatiana, et al.
Publicado: (2021)

Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma
por: Fancher,(1,2), Karen M., et al.
Publicado: (2016)

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors
por: Wang, Ninghai, et al.
Publicado: (2015)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE
por: Humbel, Morgane, et al.
Publicado: (2021)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
por: Chen, Wei-Chih, et al.
Publicado: (2017)

Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression
por: Pazina, Tatiana, et al.
Publicado: (2017)

Responses to Microbial Challenges by SLAMF Receptors
por: van Driel, Boaz Job, et al.
Publicado: (2016)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
por: Mentlik James, Ashley, et al.
Publicado: (2013)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

SLAMF6 clustering is required to augment T cell activation
por: Dragovich, Matthew A., et al.
Publicado: (2019)

Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
por: Alfarra, Helmi, et al.
Publicado: (2020)

Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
por: Tognarelli, Sara, et al.
Publicado: (2018)

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
por: Atchison, Douglas K., et al.
Publicado: (2017)

Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
por: Ide, Takafumi, et al.
Publicado: (2021)

Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
por: Shimazu, Yutaka, et al.
Publicado: (2023)

SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF Receptors
por: De Calisto, Jaime, et al.
Publicado: (2014)

SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus
por: Humbel, Morgane, et al.
Publicado: (2022)

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
por: Wang, Huihan, et al.
Publicado: (2021)

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
por: Richardson, Kelden, et al.
Publicado: (2022)

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
por: Suzuki, K, et al.
Publicado: (2017)

Advances in Understanding the Roles of CD244 (SLAMF4) in Immune Regulation and Associated Diseases
por: Sun, Lin, et al.
Publicado: (2021)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
por: Bannas, Peter, et al.
Publicado: (2018)

Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity
por: Bernard, Nicole F., et al.
Publicado: (2017)

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
por: Balasa, Balaji, et al.
Publicado: (2014)

NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma
por: Orrantia, Ane, et al.
Publicado: (2021)

SLAMF8 Downregulates Mouse Macrophage Microbicidal Mechanisms via PI3K Pathways
por: Romero-Pinedo, Salvador, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7jdtudhqveqa1kskal5gb17t7e